Artiva Biotherapeutics, Inc. announced private placement of 16,110,46 series A Preferred shares at an issue price of $5 per share for gross proceeds of $80,552,315 on June 25, 2020. The company issued preferred shares through third party capital allocation method. The transaction has been approved by the board of directors of Green Cross Holdings Corporation (KOSE:A005250). The company has raised $43,441,864 pursuant to Regulation D from 8 investors. The shares are convertible into fixed conversion price of $5 per share. The shares are non-redeemable.

On the same day, the company issued 15,600,000 shares for proceeds of $78,000,000 in its first tranche closing. The transaction included participation from new lead investors, 5AM Ventures VI, L.P., a fund managed by 5AM Venture Management LLC for 3,700,000 shares, venBio Global Strategic Fund III, L.P., a fund managed by venBio LLC for 3,700,000 shares, and RA Capital Healthcare Fund, L.P. for 2,475,340 shares, Blackwell Partners LLC-Series A for 299,660 shares, and RA Capital Nexus Fund, L.P. for 925,000 shares, funds managed by RA Capital Management, L.P. The transaction also included participation from new investor, Medivate-DA value fund No.03, managed by Medivate Partners LLC for 800,000 shares, existing investors, Green Cross Holdings Corporation (KOSE:A005250) for 1,660,000 shares, and Green Cross Lab Cell Corporation (KOSDAQ:A144510) for 440,000 shares. As a part of the transaction, Brian Daniels of 5AM Venture Management LLC, Laura Stoppel of RA Capital Management, L.P., and Yvonne Yamanaka of venBio LLC will join the company's board.